Stock Details
ABBV is AbbVie Inc.'s stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 157.24$. Average daily volumn in 3 months 5.49M. Market cap 255.74B



Stock symbol : ABBV. Exchange : NYSE. Currency : USD
Lastest price : 144.61$. Total volume : 5.74M. Market state POST
Click reload if you want to check the lastest price on market!!!

AbbVie Inc. (ABBV)
Last Price
144.61$
Change
-0.53
Volume
5.74M

Previous Close145.14
Open145.41
Day Range144.48-146.35
Bid144.72 x 1.2k
Ask144.79 x 800
Volume5.74M
Average Volume5.49M
Market Cap255.74B
Beta0.58
52 Week Range134.09-175.91
Trailing P/E19.28
Foward P/E12.41
Dividend (Yield %)4.08%
Ex-Dividend Date2023-01-12



Financial Details


According to AbbVie Inc.'s financial reports the company's revenue in 2021 were 56.2B an increase( +24.44%) over the years 2020 revenue that were of 45.8B. In 2021 the company's total earnings were 11.54B while total earnings in 2020 were 4.62B( +175%).


Loading ...



Organization

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behรงet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCL... EXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Market Cap:
255.74B
Revenue:
56.2B
Total Assets:
146.53B
Total Cash:
9.75B


News about "AbbVie Inc."

abbvie-abbv-to-report-q4-earnings-whats-in-the-cards-image

AbbVie (ABBV) to Report Q4 Earnings: What's in the Cards?

Source from : MSN - 2 days ago

AbbVie ABBV will report fourth-quarter and full-year 2022 results on Feb 9, before market open. In the last reported quarter, the company delivered an earnings surprise of 2.81%. This large ...See details»


abbvie-plans-to-lift-2-billion-cap-on-deals-wsj-image

Abbvie plans to lift $2 billion cap on deals - WSJ

Source from : Reuters on MSN - 2 days ago

A sign stands outside a Abbvie facility in Cambridge, Massachusetts, U.S., May 20, 2021. REUTERS/Brian Snyder/ ...See details»


investors-heavily-search-abbvie-inc-abbv-here-is-what-you-need-to-know-image

Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know

Source from : MSN - 5 days ago

AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence ...See details»


abbvie-q4-results-in-focus-with-eye-on-new-drugs-as-humira-challengers-enter-us-doors-image

AbbVie Q4 results in focus with eye on new drugs as Humira challengers enter US doors

Source from : Seeking Alpha on MSN - 16 hours ago

AbbVie (ABBV) is scheduled to announce Q4 earnings results on Thursday, February 9th, before market open.The consensus EPS Estimate is $3.58 (+8.2% Y/Y) and the consensus ...See details»


abbvie-inc-nyseabbv-is-a-favorite-amongst-institutional-investors-who-own-70-image

AbbVie Inc. (NYSE:ABBV) is a favorite amongst institutional investors who own 70%

Source from : YAHOO!Finance - 7 days ago

Every investor in AbbVie Inc. ( NYSE:ABBV ) should be aware of the most powerful shareholder groups. And the group ...See details»


is-abbvie-abbv-an-attractive-investment-option-image

Is AbbVie (ABBV) an Attractive Investment Option?

Source from : Insider Monkey - 6 days ago

Alger Capital, an investment management company, released its โ€œAlger Spectra Fundโ€ fourth quarter investor letter. A copy of the same can be downloaded here.See details»


abbvie-inc-stock-rises-tuesday-still-underperforms-market-image

AbbVie Inc. stock rises Tuesday, still underperforms market

Source from : MarketWatch - 8 days ago

Shares of AbbVie Inc. rallied 1.44% to $147.75 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P ...See details»


AbbVie Inc.

Source from : Wall Street Journal - 3 month ago

No significant news for in the past two years. Key Stock Data P/E Ratio (TTM) The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...See details»


AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know

Source from : Yahoo - 16 days ago

AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.See details»


AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It

Source from : Yahoo News - 1 month ago

AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares ...See details»


AbbVie Inc. (ABBV) Just Got Our Attention

Source from : newsheater - 6 month ago

AbbVie Inc. (NYSE:ABBV) went down by -0.12% from its latest closing price compared to the recent 1-year high of $175.91. The companyโ€™s stock price has collected -0.43% of loss in the last five trading ...See details»


AbbVie Inc. Common Stock (ABBV)

Source from : Nasdaq - 1 year ago

*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green highlights the top performing ETF by % change in the past ...See details»


PAC Profile: AbbVie Inc

Source from : OpenSecrets.org - 2 years ago

*Based on data released by the Federal Election Commission on January 15, 2023 except for independent expenditure and communication cost, contributions to federal candidates, and contributions from ...See details»


What Makes AbbVie (ABBV) Stock Attractive?

Source from : Yahoo! Sports - 9 days ago

Baron Funds, an investment management company, released its โ€œBaron Health Care Fundโ€ fourth quarter 2022 investor letter. A copy of the same can be downloaded here. In the fourth quarter, the fund ...See details»